MedPath

Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2
Completed
Conditions
Endometrial Cancer
Registration Number
NCT00023894
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or persistent endometrial cancer.

Detailed Description

OBJECTIVES:

* Determine the antitumor activity of flavopiridol in patients with recurrent or persistent endometrial carcinoma.

* Determine the nature and degree of toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 10-24 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (54)

University of Alabama at Birmingham Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

Jonsson Comprehensive Cancer Center, UCLA

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Community Hospital of Los Gatos

πŸ‡ΊπŸ‡Έ

Los Gatos, California, United States

Chao Family Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Orange, California, United States

University of Colorado Cancer Center

πŸ‡ΊπŸ‡Έ

Denver, Colorado, United States

Walter Reed Army Medical Center

πŸ‡ΊπŸ‡Έ

Washington, District of Columbia, United States

H. Lee Moffitt Cancer Center and Research Institute

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Rush-Presbyterian-St. Luke's Medical Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

University of Chicago Cancer Research Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Indiana University Cancer Center

πŸ‡ΊπŸ‡Έ

Indianapolis, Indiana, United States

Scroll for more (44 remaining)
University of Alabama at Birmingham Comprehensive Cancer Center
πŸ‡ΊπŸ‡ΈBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.